Returns Chart

Returns Chart

Key Stats

Net Expense Ratio Total Assets Under Management Weighted Average Dividend Yield Turnover Ratio (Generic)
0.68% 3.342B 0.63% 52.00%
1 Year Fund Level Flows 1 Year Total Returns (Daily) Annualized Total Returns Since Inception (Daily) Max Drawdown (Since Inception)
-833.33M 33.05%

Basic Info

Investment Strategy
The Fund seeks capital appreciation. Fidelity normally invests the Fund's assets primarily in common stocks. Fidelity normally invests at least 80% of the Fund's assets in securities of companies primarily engaged in the design, manufacture, or sale of products or services used in connection with health care or medicine.
General
Security Type Mutual Fund
Equity Style Multi Cap Core
Broad Asset Class Sector Equity
Broad Category Equity
Global Peer Group Equity Sector Healthcare
Peer Group Health/Biotechnology Funds
Global Macro Equity Industry Sector
US Macro Sector Equity Funds
YCharts Categorization --
YCharts Benchmark --
Prospectus Objective Health/Biotechnology Funds
Fund Owner Firm Name Fidelity Investments
Broad Asset Class Benchmark Index
^MSWNTR 100.0%

View Basic Info
Start Trial

Net Fund Flows Versus Peer Group

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: 91
-118.50M Peer Group Low
768.70M Peer Group High
1 Year
% Rank: 93
-833.33M
-1.952B Peer Group Low
1.887B Peer Group High
3 Months
% Rank: 92
-377.52M Peer Group Low
1.330B Peer Group High
3 Years
% Rank: 92
-7.717B Peer Group Low
963.31M Peer Group High
6 Months
% Rank: 92
-2.065B Peer Group Low
1.150B Peer Group High
5 Years
% Rank: 92
-8.959B Peer Group Low
1.534B Peer Group High
YTD
% Rank: 93
-1.141B Peer Group Low
982.49M Peer Group High
10 Years
% Rank: 83
-12.70B Peer Group Low
5.702B Peer Group High
Date Unavailable

Performance Versus Peer Group

 
20%
15%
10%
5%
0
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (NAV)
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
Peer Group Rtn. (NAV)
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
% Rank in Peer Group (NAV)
5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
View Performance Versus Peer Group
Start Trial

Annual Total Returns Versus Peers

Loading chart...
Name
2019
2020
2021
2022
2023
2024
2025
YTD
28.22%
21.40%
11.47%
-12.84%
4.07%
4.17%
14.52%
16.23%
27.67%
15.90%
21.82%
-18.14%
23.79%
18.67%
21.09%
11.33%
26.07%
32.53%
-3.29%
-7.74%
10.99%
5.61%
39.93%
27.81%
21.97%
18.24%
20.50%
-5.50%
2.48%
2.65%
15.43%
10.12%
29.25%
30.27%
13.40%
-12.08%
3.22%
1.94%
17.89%
12.12%
18.58%
41.67%
6.29%
-10.06%
12.63%
8.81%
19.59%
8.72%
As of September 17, 2026.

Fundamentals

General
Distribution Yield --
Dividend Yield TTM (9-15-26) 0.40%
30-Day SEC Yield (10-3-23) 0.00%
7-Day SEC Yield (10-3-23) 0.00%
Number of Holdings 141
Stock
Weighted Average PE Ratio 38.30
Weighted Average Price to Sales Ratio 10.76
Weighted Average Price to Book Ratio 8.894
Weighted Median ROE 246.4%
Weighted Median ROA -5.06%
Return on Investment (TTM) -2.39%
Earning Yield 0.0285
LT Debt / Shareholders Equity 0.7581
Number of Equity Holdings 134
As of July 31, 2026

Growth Metrics

EPS Growth (1Y) 23.82%
EPS Growth (3Y) 6.17%
EPS Growth (5Y) 9.85%
Sales Growth (1Y) 20.96%
Sales Growth (3Y) 18.90%
Sales Growth (5Y) 17.75%
Sales per Share Growth (1Y) 125.4%
Sales per Share Growth (3Y) 19.29%
Operating Cash Flow - Growth Rate (3Y) 10.62%
As of July 31, 2026

Asset Allocation

As of July 31, 2026.
Type % Net
Cash 0.11%
Stock 97.75%
Bond 0.31%
Convertible 0.00%
Preferred 1.99%
Other -0.17%
View Asset Allocation
Start Trial

Top 10 Holdings

Name % Weight Price % Change
Eli Lilly & Co. 7.66% 1138.22 0.19%
Danaher Corp. 6.75% 208.50 -0.41%
Thermo Fisher Scientific, Inc. 6.31% 648.56 1.12%
UnitedHealth Group, Inc. 4.17% 375.34 -0.16%
Johnson & Johnson 3.78% 267.38 0.07%
AbbVie, Inc. 3.62% 262.58 -0.17%
argenx SE 2.09% 985.37 0.57%
Merck & Co., Inc. 2.09% 144.95 0.81%
West Pharmaceutical Services, Inc. 2.06% 362.00 -0.82%
Ascendis Pharma A/S 1.95% 247.62 3.27%

Fees & Availability

Fees
Actual 12B-1 Fee --
Actual Management Fee 0.67%
Administration Fee --
Maximum Front Load --
Maximum Deferred Load --
Maximum Redemption Fee 0.00%
General Availability
Available for Insurance Product No
Available for RRSP No
Purchase Details
Open to New Investors Yes
Minimum Initial Investment 0.00 None
Minimum Subsequent Investment 0.00 None

TTM Distributions

View TTM Distributions. Upgrade now.
Type Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug
Qualified Income
-- -- -- -- -- -- -- -- -- -- -- --
Normal
-- -- -- -- -- -- -- -- -- -- -- --
Qualified
-- -- -- -- -- -- -- -- -- -- -- --
LT Cap Gains
-- -- -- -- -- -- -- -- -- -- -- --
Ordinary Income
-- -- -- -- -- -- -- -- -- -- -- --
Non-Qual
-- -- -- -- -- -- -- -- -- -- -- --
ST Cap Gains
-- -- -- -- -- -- -- -- -- -- -- --
Interest
-- -- -- -- -- -- -- -- -- -- -- --
Tax-Exempt
-- -- -- -- -- -- -- -- -- -- -- --
ROC
-- -- -- -- -- -- -- -- -- -- -- --
Other
-- -- -- -- -- -- -- -- -- -- -- --
Total
-- -- -- -- -- -- -- -- -- -- -- --
As of August 31, 2026.

Basic Info

Investment Strategy
The Fund seeks capital appreciation. Fidelity normally invests the Fund's assets primarily in common stocks. Fidelity normally invests at least 80% of the Fund's assets in securities of companies primarily engaged in the design, manufacture, or sale of products or services used in connection with health care or medicine.
General
Security Type Mutual Fund
Equity Style Multi Cap Core
Broad Asset Class Sector Equity
Broad Category Equity
Global Peer Group Equity Sector Healthcare
Peer Group Health/Biotechnology Funds
Global Macro Equity Industry Sector
US Macro Sector Equity Funds
YCharts Categorization --
YCharts Benchmark --
Prospectus Objective Health/Biotechnology Funds
Fund Owner Firm Name Fidelity Investments
Broad Asset Class Benchmark Index
^MSWNTR 100.0%

View Basic Info
Start Trial

Fundamentals

General
Distribution Yield --
Dividend Yield TTM (9-15-26) 0.40%
30-Day SEC Yield (10-3-23) 0.00%
7-Day SEC Yield (10-3-23) 0.00%
Number of Holdings 141
Stock
Weighted Average PE Ratio 38.30
Weighted Average Price to Sales Ratio 10.76
Weighted Average Price to Book Ratio 8.894
Weighted Median ROE 246.4%
Weighted Median ROA -5.06%
Return on Investment (TTM) -2.39%
Earning Yield 0.0285
LT Debt / Shareholders Equity 0.7581
Number of Equity Holdings 134
As of July 31, 2026

Growth Metrics

EPS Growth (1Y) 23.82%
EPS Growth (3Y) 6.17%
EPS Growth (5Y) 9.85%
Sales Growth (1Y) 20.96%
Sales Growth (3Y) 18.90%
Sales Growth (5Y) 17.75%
Sales per Share Growth (1Y) 125.4%
Sales per Share Growth (3Y) 19.29%
Operating Cash Flow - Growth Rate (3Y) 10.62%
As of July 31, 2026

Fund Details

Key Dates
Inception Date 9/3/1996
Last Annual Report Date 7/31/2025
Last Prospectus Date 9/29/2025
Share Classes
FACDX A
FACTX M
FHCCX C
FIKCX Z
Attributes
Index Fund --
Inverse Fund No
Leveraged Fund --
Fund of Funds No
Currency Hedged Fund --
Socially Responsible Fund No

Top Portfolio Holders

Name % Weight
Portfolio A 5.00%
Portfolio B 3.50%
Portfolio C 2.25%
View Top Portfolio Holders
Start Trial

Excel Add-In Codes

Name: =YCI("M:FHCIX", "name")
Broad Asset Class: =YCI("M:FHCIX", "broad_asset_class")
Broad Category: =YCI("M:FHCIX", "broad_category_group")
Prospectus Objective: =YCI("M:FHCIX", "prospectus_objective")
To find the codes for any of our securities and financial metrics, see our Complete Excel Reference.
View Excel Add-In Codes
Start Trial